These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 30190343

  • 21. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
    Ogura M, Itoh K, Kinoshita T, Fukuda H, Takenaka T, Ohtsu T, Kagami Y, Tobinai K, Okamoto M, Asaoku H, Sasaki T, Mikuni C, Hirano M, Chou T, Ohnishi K, Ohno H, Nasu K, Okabe K, Ikeda S, Nakamura S, Hotta T, Shimoyama M.
    Int J Hematol; 2010 Dec; 92(5):713-24. PubMed ID: 21076995
    [Abstract] [Full Text] [Related]

  • 22. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Andrieu JM, Colonna P.
    J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
    [No Abstract] [Full Text] [Related]

  • 23. Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.
    Hay AE, Meyer RM.
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):49-63. PubMed ID: 24287067
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15-year follow-up of the ABVDDD-DI phase II study.
    Corazzelli G, Cuccaro A, Morelli E, Arcamone M, De Chiara A, Paccone A, Petrillo A, Ibello F, Aversa C, Esposito M, Volzone F, Saggese M, Capobianco G, Sarno S, Sirica L, Crisci S, De Filippi R, Pinto A.
    Br J Haematol; 2024 Oct; 205(4):1383-1388. PubMed ID: 39091109
    [Abstract] [Full Text] [Related]

  • 26. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
    Seshachalam A, Karpurmath SV, Rathnam K, Raman SG, Janarthinakani M, Prasad K, Patil C, Anoop P, Reddy N, Anumula SK, Roopa SP, Golamari KR, Danthala M, Gunari P, Malipatil B, Rangarajan B, Udupa KS, Nandennavar M, Niraimathi K, Shewade HD.
    J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
    [Abstract] [Full Text] [Related]

  • 27. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
    Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE.
    Blood; 2012 May 03; 119(18):4123-8. PubMed ID: 22371887
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
    Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM.
    Lancet Oncol; 2013 Dec 03; 14(13):1348-56. PubMed ID: 24239220
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pohl-Pinkus constrictions of hair following chemotherapy for Hodgkin's disease.
    Williamson PJ, de Berker D.
    Br J Haematol; 2005 Mar 03; 128(5):582. PubMed ID: 15725077
    [No Abstract] [Full Text] [Related]

  • 32. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A, Ha FJ, Chong G, Grigg A, Mckendrick J, Schwarer AP, Doig R, Hamid A, Hawkes EA.
    Ann Hematol; 2016 Apr 03; 95(5):809-16. PubMed ID: 26878861
    [Abstract] [Full Text] [Related]

  • 33. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
    Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, Diehl V, Borchmann P, Engert A, von Tresckow B.
    Lancet Haematol; 2021 Apr 03; 8(4):e278-e288. PubMed ID: 33770483
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
    Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM.
    Blood; 2011 Oct 27; 118(17):4585-90. PubMed ID: 21873543
    [Abstract] [Full Text] [Related]

  • 36. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
    Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dörken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM, Conducted by the NCIC Clinical Trials Group (Canada) and German Hodgkin Study Group (GHSG).
    Ann Oncol; 2013 Dec 27; 24(12):3065-9. PubMed ID: 24121121
    [Abstract] [Full Text] [Related]

  • 37. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
    Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM.
    Blood; 2019 Aug 15; 134(7):606-613. PubMed ID: 31186274
    [Abstract] [Full Text] [Related]

  • 38. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.
    Pavone V, Ricardi U, Luminari S, Gobbi P, Federico M, Baldini L, Iannitto E, Ucci G, Marcheselli L, Orsucci L, Angelucci E, Liberati M, Gavarotti P, Levis A, Intergruppo Italiano Linfomi (IIL).
    Ann Oncol; 2008 Apr 15; 19(4):763-8. PubMed ID: 18180244
    [Abstract] [Full Text] [Related]

  • 39. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
    Carella AM, Corradini P, Mussetti A, Ricardi U, Vitolo U, Viviani S.
    Ann Hematol; 2018 Aug 15; 97(8):1301-1315. PubMed ID: 29802458
    [Abstract] [Full Text] [Related]

  • 40. Induction therapy for advanced-stage Hodgkin lymphoma: late intensification (ABVD chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse).
    Ansell SM.
    Hematol Oncol Clin North Am; 2014 Feb 15; 28(1):75-86. PubMed ID: 24287069
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.